Plasma miRNAs as early biomarkers for detecting hepatocellular carcinoma

Yang Wen, Jing Han, Jianguo Chen, Jing Dong, Yongxiang Xia, Jibin Liu, Yue Jiang, Juncheng Dai, Jianhua Lu, Guangfu Jin, Jiali Han, Qingyi Wei, Hongbing Shen, Beicheng Sun, Zhibin Hu

Research output: Contribution to journalArticle

99 Citations (Scopus)

Abstract

The early detection of hepatocellular carcinoma (HCC) presents a challenge because of the lack of specific biomarkers. Serum/plasma microRNAs (miRNAs) can discriminate HCC patients from controls. We aimed to identify and evaluate HCC-associated plasma miRNAs originating from the liver as early biomarkers for detecting HCC. In this multicenter three-phase study, we first performed screening using both plasma (HCC before and after liver transplantation or liver hepatectomy) and tissue samples (HCC, para-carcinoma and cirrhotic tissues). Then, we evaluated the diagnostic potential of the miRNAs in two case-control studies (training and validation sets). Finally, we used two prospective cohorts to test the potential of the identified miRNAs for the early detection of HCC. During the screening phase, we identified ten miRNAs, eight of which (miR-20a-5p, miR-25-3p, miR-30a-5p, miR-92a-3p, miR-132-3p, miR-185-5p, miR-320a and miR-324-3p) were significantly overexpressed in the HBV-positive HCC patients compared with the HBV-positive cancer-free controls in both the training and validation sets, with a sensitivity of 0.866 and specificity of 0.646. Furthermore, we assessed the potential for early HCC detection of these eight newly identified miRNAs and three previously reported miRNAs (miR-192-5p, miR-21-5p and miR-375) in two prospective cohorts. Our meta-analysis revealed that four miRNAs (miR-20a-5p, miR-320a, miR-324-3p and miR-375) could be used as preclinical biomarkers (pmeta < 0.05) for HCC. The expression profile of the eight-miRNA panel can be used to discriminate HCC patients from cancer-free controls, and the four-miRNA panel (alone or combined with AFP) could be a blood-based early detection biomarker for HCC screening.

Original languageEnglish (US)
Pages (from-to)1679-1690
Number of pages12
JournalInternational Journal of Cancer
Volume137
Issue number7
DOIs
StatePublished - Jan 1 2015

Fingerprint

MicroRNAs
Hepatocellular Carcinoma
Biomarkers
Liver
Hepatectomy
Liver Transplantation
Meta-Analysis
Case-Control Studies
Neoplasms
Carcinoma
Sensitivity and Specificity

Keywords

  • biomarker
  • early detection
  • hepatocellular carcinoma
  • miRNA
  • plasma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Wen, Y., Han, J., Chen, J., Dong, J., Xia, Y., Liu, J., ... Hu, Z. (2015). Plasma miRNAs as early biomarkers for detecting hepatocellular carcinoma. International Journal of Cancer, 137(7), 1679-1690. https://doi.org/10.1002/ijc.29544

Plasma miRNAs as early biomarkers for detecting hepatocellular carcinoma. / Wen, Yang; Han, Jing; Chen, Jianguo; Dong, Jing; Xia, Yongxiang; Liu, Jibin; Jiang, Yue; Dai, Juncheng; Lu, Jianhua; Jin, Guangfu; Han, Jiali; Wei, Qingyi; Shen, Hongbing; Sun, Beicheng; Hu, Zhibin.

In: International Journal of Cancer, Vol. 137, No. 7, 01.01.2015, p. 1679-1690.

Research output: Contribution to journalArticle

Wen, Y, Han, J, Chen, J, Dong, J, Xia, Y, Liu, J, Jiang, Y, Dai, J, Lu, J, Jin, G, Han, J, Wei, Q, Shen, H, Sun, B & Hu, Z 2015, 'Plasma miRNAs as early biomarkers for detecting hepatocellular carcinoma', International Journal of Cancer, vol. 137, no. 7, pp. 1679-1690. https://doi.org/10.1002/ijc.29544
Wen, Yang ; Han, Jing ; Chen, Jianguo ; Dong, Jing ; Xia, Yongxiang ; Liu, Jibin ; Jiang, Yue ; Dai, Juncheng ; Lu, Jianhua ; Jin, Guangfu ; Han, Jiali ; Wei, Qingyi ; Shen, Hongbing ; Sun, Beicheng ; Hu, Zhibin. / Plasma miRNAs as early biomarkers for detecting hepatocellular carcinoma. In: International Journal of Cancer. 2015 ; Vol. 137, No. 7. pp. 1679-1690.
@article{86effbbd9e48462ba1be7d4a2cef5791,
title = "Plasma miRNAs as early biomarkers for detecting hepatocellular carcinoma",
abstract = "The early detection of hepatocellular carcinoma (HCC) presents a challenge because of the lack of specific biomarkers. Serum/plasma microRNAs (miRNAs) can discriminate HCC patients from controls. We aimed to identify and evaluate HCC-associated plasma miRNAs originating from the liver as early biomarkers for detecting HCC. In this multicenter three-phase study, we first performed screening using both plasma (HCC before and after liver transplantation or liver hepatectomy) and tissue samples (HCC, para-carcinoma and cirrhotic tissues). Then, we evaluated the diagnostic potential of the miRNAs in two case-control studies (training and validation sets). Finally, we used two prospective cohorts to test the potential of the identified miRNAs for the early detection of HCC. During the screening phase, we identified ten miRNAs, eight of which (miR-20a-5p, miR-25-3p, miR-30a-5p, miR-92a-3p, miR-132-3p, miR-185-5p, miR-320a and miR-324-3p) were significantly overexpressed in the HBV-positive HCC patients compared with the HBV-positive cancer-free controls in both the training and validation sets, with a sensitivity of 0.866 and specificity of 0.646. Furthermore, we assessed the potential for early HCC detection of these eight newly identified miRNAs and three previously reported miRNAs (miR-192-5p, miR-21-5p and miR-375) in two prospective cohorts. Our meta-analysis revealed that four miRNAs (miR-20a-5p, miR-320a, miR-324-3p and miR-375) could be used as preclinical biomarkers (pmeta < 0.05) for HCC. The expression profile of the eight-miRNA panel can be used to discriminate HCC patients from cancer-free controls, and the four-miRNA panel (alone or combined with AFP) could be a blood-based early detection biomarker for HCC screening.",
keywords = "biomarker, early detection, hepatocellular carcinoma, miRNA, plasma",
author = "Yang Wen and Jing Han and Jianguo Chen and Jing Dong and Yongxiang Xia and Jibin Liu and Yue Jiang and Juncheng Dai and Jianhua Lu and Guangfu Jin and Jiali Han and Qingyi Wei and Hongbing Shen and Beicheng Sun and Zhibin Hu",
year = "2015",
month = "1",
day = "1",
doi = "10.1002/ijc.29544",
language = "English (US)",
volume = "137",
pages = "1679--1690",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "7",

}

TY - JOUR

T1 - Plasma miRNAs as early biomarkers for detecting hepatocellular carcinoma

AU - Wen, Yang

AU - Han, Jing

AU - Chen, Jianguo

AU - Dong, Jing

AU - Xia, Yongxiang

AU - Liu, Jibin

AU - Jiang, Yue

AU - Dai, Juncheng

AU - Lu, Jianhua

AU - Jin, Guangfu

AU - Han, Jiali

AU - Wei, Qingyi

AU - Shen, Hongbing

AU - Sun, Beicheng

AU - Hu, Zhibin

PY - 2015/1/1

Y1 - 2015/1/1

N2 - The early detection of hepatocellular carcinoma (HCC) presents a challenge because of the lack of specific biomarkers. Serum/plasma microRNAs (miRNAs) can discriminate HCC patients from controls. We aimed to identify and evaluate HCC-associated plasma miRNAs originating from the liver as early biomarkers for detecting HCC. In this multicenter three-phase study, we first performed screening using both plasma (HCC before and after liver transplantation or liver hepatectomy) and tissue samples (HCC, para-carcinoma and cirrhotic tissues). Then, we evaluated the diagnostic potential of the miRNAs in two case-control studies (training and validation sets). Finally, we used two prospective cohorts to test the potential of the identified miRNAs for the early detection of HCC. During the screening phase, we identified ten miRNAs, eight of which (miR-20a-5p, miR-25-3p, miR-30a-5p, miR-92a-3p, miR-132-3p, miR-185-5p, miR-320a and miR-324-3p) were significantly overexpressed in the HBV-positive HCC patients compared with the HBV-positive cancer-free controls in both the training and validation sets, with a sensitivity of 0.866 and specificity of 0.646. Furthermore, we assessed the potential for early HCC detection of these eight newly identified miRNAs and three previously reported miRNAs (miR-192-5p, miR-21-5p and miR-375) in two prospective cohorts. Our meta-analysis revealed that four miRNAs (miR-20a-5p, miR-320a, miR-324-3p and miR-375) could be used as preclinical biomarkers (pmeta < 0.05) for HCC. The expression profile of the eight-miRNA panel can be used to discriminate HCC patients from cancer-free controls, and the four-miRNA panel (alone or combined with AFP) could be a blood-based early detection biomarker for HCC screening.

AB - The early detection of hepatocellular carcinoma (HCC) presents a challenge because of the lack of specific biomarkers. Serum/plasma microRNAs (miRNAs) can discriminate HCC patients from controls. We aimed to identify and evaluate HCC-associated plasma miRNAs originating from the liver as early biomarkers for detecting HCC. In this multicenter three-phase study, we first performed screening using both plasma (HCC before and after liver transplantation or liver hepatectomy) and tissue samples (HCC, para-carcinoma and cirrhotic tissues). Then, we evaluated the diagnostic potential of the miRNAs in two case-control studies (training and validation sets). Finally, we used two prospective cohorts to test the potential of the identified miRNAs for the early detection of HCC. During the screening phase, we identified ten miRNAs, eight of which (miR-20a-5p, miR-25-3p, miR-30a-5p, miR-92a-3p, miR-132-3p, miR-185-5p, miR-320a and miR-324-3p) were significantly overexpressed in the HBV-positive HCC patients compared with the HBV-positive cancer-free controls in both the training and validation sets, with a sensitivity of 0.866 and specificity of 0.646. Furthermore, we assessed the potential for early HCC detection of these eight newly identified miRNAs and three previously reported miRNAs (miR-192-5p, miR-21-5p and miR-375) in two prospective cohorts. Our meta-analysis revealed that four miRNAs (miR-20a-5p, miR-320a, miR-324-3p and miR-375) could be used as preclinical biomarkers (pmeta < 0.05) for HCC. The expression profile of the eight-miRNA panel can be used to discriminate HCC patients from cancer-free controls, and the four-miRNA panel (alone or combined with AFP) could be a blood-based early detection biomarker for HCC screening.

KW - biomarker

KW - early detection

KW - hepatocellular carcinoma

KW - miRNA

KW - plasma

UR - http://www.scopus.com/inward/record.url?scp=84943348363&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943348363&partnerID=8YFLogxK

U2 - 10.1002/ijc.29544

DO - 10.1002/ijc.29544

M3 - Article

C2 - 25845839

AN - SCOPUS:84943348363

VL - 137

SP - 1679

EP - 1690

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 7

ER -